Q - Cyclerion Therapeutics,

On August 4, 2025, the Company entered into a Consulting Agreement with Rhonda Chicko, effective as of such date, under which Ms. Chicko receives compensation as the Corporation’s Chief Financial Officer, at the rate of $525.00 per hour and is entitled to receive a stock option grant to purchase up to 25,000 shares of the Corporation’s Common Stock, subject to certain vesting requirements, all as described in further detail in the Consulting Agreement attached to this Form 10-Q as Exhibit 10.1. The description of the Consulting Agreement in this Item 5 of this Report on Form 10-Q is not complete and is qualified in its entirety by reference to the complete text of the Consulting Agreement, a copy of which is attached as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference”.

During the 2025 second quarter, no director or Section 16 officer adopted orterminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements.